Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Features

Run, Walk, Bike: Doctors Open Up About Their Own Heart-Healthy Exercise Habits

Michael O'Riordan

November 11, 2016

News Daily News

Increased Sedentary Time Ups Risk for CVD, Diabetes, and Death, the AHA Says

Leah Lawrence

August 18, 2016

News Daily News

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

L.A. McKeown

July 28, 2016

News Daily News

Pokémon Go Forth: Cardiologists, AHA Support Use of Augmented Reality Games That Encourage Movement

Yael L. Maxwell

July 22, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Industry News

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

January 24, 2016

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

Advertisement

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Run, Walk, Bike: Doctors Open Up About Their Own Heart-Healthy Exercise Habits

Increased Sedentary Time Ups Risk for CVD, Diabetes, and Death, the AHA Says

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

Pokémon Go Forth: Cardiologists, AHA Support Use of Augmented Reality Games That Encourage Movement

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content